Last updated on October 2018

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Brief description of study

This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants will be randomized by a 1:1 ratio into atezolizumab group or control group.

Clinical Study Identifier: NCT02450331

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: WO29636 ...

Vitebsk Regional Clinical Oncology Dispensary
Vitebsk, Belarus